ACOTEC SCIEN.H. DL-00001 (7W3) - Total Assets
Based on the latest financial reports, ACOTEC SCIEN.H. DL-00001 (7W3) holds total assets worth €1.83 Billion EUR (≈ $2.14 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ACOTEC SCIEN.H. DL-00001 net assets for net asset value and shareholders' equity analysis.
ACOTEC SCIEN.H. DL-00001 - Total Assets Trend (2021–2024)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's total assets have evolved over time, based on quarterly financial data.
ACOTEC SCIEN.H. DL-00001 - Asset Composition Analysis
Current Asset Composition (December 2024)
ACOTEC SCIEN.H. DL-00001's total assets of €1.83 Billion consist of 72.8% current assets and 27.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 45.2% |
| Accounts Receivable | €161.10 Million | 9.7% |
| Inventory | €155.99 Million | 9.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €47.49 Million | 2.9% |
| Goodwill | €1.15 Million | 0.1% |
Asset Composition Trend (2021–2024)
This chart illustrates how ACOTEC SCIEN.H. DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 7W3 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACOTEC SCIEN.H. DL-00001's current assets represent 72.8% of total assets in 2024, a decrease from 95.1% in 2021.
- Cash Position: Cash and equivalents constituted 45.2% of total assets in 2024, down from 87.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 9.7% of total assets.
ACOTEC SCIEN.H. DL-00001 Competitors by Total Assets
Key competitors of ACOTEC SCIEN.H. DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
ACOTEC SCIEN.H. DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 6.84 | 6.84 |
| Quick Ratio | 5.57 | 6.10 | 6.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.13 Billion | €1.11 Billion | €1.11 Billion |
ACOTEC SCIEN.H. DL-00001 - Advanced Valuation Insights
This section examines the relationship between ACOTEC SCIEN.H. DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | 3.2% |
| Total Assets | €1.66 Billion |
| Market Capitalization | $377.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values ACOTEC SCIEN.H. DL-00001's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: ACOTEC SCIEN.H. DL-00001's assets grew by 3.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for ACOTEC SCIEN.H. DL-00001 (2021–2024)
The table below shows the annual total assets of ACOTEC SCIEN.H. DL-00001 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.66 Billion ≈ $1.94 Billion |
+3.20% |
| 2023-12-31 | €1.61 Billion ≈ $1.88 Billion |
+14.22% |
| 2022-12-31 | €1.41 Billion ≈ $1.65 Billion |
+7.89% |
| 2021-12-31 | €1.31 Billion ≈ $1.53 Billion |
-- |
About ACOTEC SCIEN.H. DL-00001
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with… Read more